| Project/Area Number |
09671304
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
SHIMIZU Shigeomi Osaka University Medical School, assistant professor, 医学部, 助手 (70271020)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
EGUCHI Yutaka Osaka University Medical School, associate professor, 医学部, 助教授 (20243206)
上池 渉 大阪大学, 医学部, 助教授 (40152847)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 1998: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1997: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | caspase-3(CPP32 / Yama) / Bcl-2 / apoptosis / yama / cpp32 |
|---|
| Research Abstract |
Caspase-3 is a member of the cysteine protease family, which plays a crucial role in apoptosis.We applied the human caspase-3 gene as a novel form of anticancer gene therapy.Overexpression of human caspase-3 alone could not induce apoptosis of tumor cell lines, whereas apoptosis was markedly enhanced by the addition of VP-16.In an AH13O liver tumor model, transfection of human caspase-3, but not the empty vector, induced extensive apoptosis and reduced tumor volume, when applied together with VP-16.However, these effect was not observed with a Bcl-2 overexpressing tumor.In conclusion, caspase-3 gene transfection accompanied by an additional death stimulus may be useful anticancer gene therapy, except for Bcl-2 overexpressing tumors.
|
